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Abstract
Ulcerative colitis (UC) is a disease of the colon and rectum character-
ized by a nonspecific chronic inflammation mediated by the concerted
response of cellular and humoral events. Prostaglandins are synthe-
sized by cyclooxygenase (COX)-1 and -2 and exhibit both pro- and
anti-inflammatory activity. To evaluate COX-1 and COX-2 immuno-
expression in 42 cases of UC and to correlate it with clinicopathologi-
cal parameters, COX-1 and COX-2 expression was investigated by the
immunohistochemistry method. Only patients with all pertinent clini-
cal and evolutive data as well as with adequate biopsy material were
included in the study. Fifteen samples of colorectal adenocarcinoma
and 14 of large bowel with no histological changes were used for
positive and negative controls, respectively. UC patients showed
COX-1 immunoreactivity in epithelial cells in 29% of the cases and in
inflammatory cells in 43%. COX-2 positivity in epithelial and inflam-
matory cells was found in 69% of the samples. The comparison
between UC and the control groups revealed that the UC group had
significantly more positive cases for COX-1 and COX-2 in inflamma-
tory cells. Immunohistochemistry allowed the identification of COX-
1 and COX-2 expression in epithelial and inflammatory cells in UC
biopsies. No significant difference between COX-1 and COX-2 im-
munoreactivity in epithelial and inflammatory cells was observed
regarding the clinicopathological parameters. COX-2 presented low
expression in normal colon and high expression in colorectal adeno-
carcinoma. COX-2 might play a role in the pathophysiologic pro-
cesses of inflammatory bowel disease and the development of neopla-
sia. Treatment with selective COX-2 inhibitors might be an additional
option for therapy.
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Introduction
Ulcerative colitis (UC), which belongs to
the spectrum of inflammatory bowel disease
(IBD), is a disease of the colon and rectum of
unknown etiology which is characterized by
a nonspecific chronic inflammation restricted
to the mucosal and submucosal layers and
mediated by a concerted response of cellular
and humoral events (1). Prostaglandins (PGs),
thromboxanes, and leukotrienes represent the
eicosatetranoic (arachidonic) acid metabo-
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lites that are collectively referred to as eico-
sanoids. PGs are produced via the cyclooxy-
genase (COX) pathway and exhibit both
pro- and anti-inflammatory effects (2). COX
is now known to exist in three isoforms:
COX-1, COX-2, and COX-3. COX-1 is a
constitutively expressed 66-kDa enzyme,
showing low or no expression in a variety of
tissues (3,4) including the intestine and co-
lon (2). The COX-1 gene is considered to be
a housekeeping gene and is believed to main-
tain the cell integrity of the gastrointestinal
tract (2,5), the regulation of blood flow
through the kidneys, and platelet aggrega-
tion (6). COX-2 is an interferon-γ-induced
70-kDa enzyme which presents 61% homol-
ogy to COX-1 (7). The enzyme is induced in
response to cellular activation mediated by
hormones, pro-inflammatory cytokines and
growth factors. It is an important mediator of
the inflammatory process (2,5) and carcino-
genesis, as well as in the progression of a
newly developed carcinoma (8,9). COX-3,
possibly a variant of COX-1 since it is de-
rived from the same gene, has been demon-
strated in vitro in macrophage cell lines, and
is mainly found in the cerebral cortex, spinal
cord and heart (10,11).
There are markedly elevated levels of
PGs in the mucosa and rectal dialysates from
IBD patients (12). The increased release of
PGE2 observed in UC may therefore origi-
nate from a relatively small number of re-
cruited inflammatory cells (13). The cellular
origin of these PGs and the relative contribu-
tions of COX-1 and COX-2 to their produc-
tion have not been fully investigated.
The objectives of the present study were
to analyze the immunoexpression of COX-1
and COX-2 proteins in biopsies from UC
patients and to correlate it with histopatho-
logical parameters and clinical follow-up.
Patients and Methods
Biopsies from the files of the Department
of Pathology, obtained from 42 consecutive
patients with UC seen at the Inflammatory
Bowel Disease Clinic of the Gastroenterol-
ogy Division, Paulista Medical School, São
Paulo Federal University, were studied. Only
patients with all pertinent clinical and evolu-
tive data as well as with adequate biopsy
material were included in the study. Patient
characteristics, including gender, age, dis-
ease extension, and clinical activity were
obtained from the medical records. All pro-
cedures were approved by the Ethics Com-
mittee of the Institution. Fifteen samples of
colorectal adenocarcinoma and 14 of large
bowel with no histological changes were
randomly selected for positive and negative
controls, respectively.
Histopathological analysis
Three-micrometer thick sections of each
block stained with hematoxylin-eosin were
reviewed independently by two pathologists.
The following parameters were analyzed:
presence (+) or absence (-) of edema, ero-
sion/ulceration, crypt abscesses, lymphoid
aggregates, lamina propria lymphoplasmocy-
tosis, mucin depletion, and Paneth cell meta-
plasia; presence (1-3+) or absence (-) of
acute inflammation in the lamina propria,
where 1+ = focal crypt epithelial polymorphs,
2+ = diffuse crypt epithelial polymorphs,
and 3+ = polymorph exudate; presence (1-
3+) or absence (-) of architectural distortion,
where 1+ = focal crypt architectural irregu-
larity, 2+ = diffuse crypt architectural ir-
regularity, and 3+ = mucosal atrophy.
Immunohistochemical analysis
Immunohistochemistry for COX-1 (Cay-
man Chemical Co., Ann Arbor, MI, USA,
Cat. No. 160110) and COX-2 (Cayman
Chemical Co., Cat. No. 160112) was carried
out according to manufacturer instructions
using the labeled streptavidin-biotin-peroxi-
dase complex system (Dako, Carpinteria,
CA, USA). The tissues were incubated with
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commercial monoclonal antibodies diluted
1:120 (COX-1) and 1:100 (COX-2) after
microwave antigen retrieval (20 min in cit-
rate buffer, pH 6.0). Sections known to ex-
press high levels of COX-1 and COX-2 were
included as positive controls, while negative
control slides omitted the primary antibody.
Evaluation of staining
Evaluation of COX-1 and COX-2 reactiv-
ity was performed according to a previously
described scoring system (14) with staining
intensity graded as 1 (weak), 2 (moderate), or
3 (strong), and the positively stained area as 0
(<10%), 1 (10-40%), 2 (40-70%), and 3
(≥70%). Both parameters were evaluated in
the cytoplasm of epithelial and inflammatory
cells. Total scores for grade and area classified
as ≥3 were defined as positive expression and
those classified as <3 as negative.
Statistical analysis
Data are reported as means ± SD. The chi-
square test and Fisher’s exact probability test,
where appropriate, were used to correlate the
immunoexpression of COX-1 and COX-2
with the clinicopathological parameters. The
Kruskal-Wallis test was used for comparison
between the UC and control groups. A P value
<0.05 was considered statistically significant.
Results
Socio-demographic and clinical-evolutive
variables
Among the 42 UC patients, 55% were
females and 57% Caucasians. Mean age at
diagnosis was 42.0 ± 15.1 years, and mean
disease duration was 5.0 ± 6.4 years. Re-
garding disease extension, 40% of the pa-
tients had proctosigmoiditis, 43% pancolitis
and 17% left-sided colitis. According to True-
love and Witt’s (15) clinical activity score,
activity was mild in 64% of the patients,
moderate in 7% and severe in 17%.
Histopathological findings
Edema and architectural distortion were
present in all samples (1+: 22%, 2+: 45%,
3+: 33%). Erosion/ulceration was observed
in 81% of the samples, acute inflammation
in 93% (1+: 17%, 2+: 43%, 3+: 33%), crypt
abscesses in 74%, lymphoid aggregates in
50%, and lamina propria lymphoplasmocy-
tosis in 83%. Paneth cell metaplasia was
identified in 24% of cases, and mucin deple-
tion in 38%.
Immunohistochemistry
COX-1 immunoreactivity was positive
in epithelial cells in 29% of cases, both at the
surface and in the crypts, and in inflamma-
tory cells in 43% of cases. COX-2 positivity
in epithelial (crypts and surface) and inflam-
matory cells were found in 69% of the pa-
tients. The immunolocalization of the pro-
teins was cytoplasmic and the reactive in-
flammatory immunopositive cells were mon-
onuclear cells and leukocytes.
The correlation between positive and
negative COX-1 and COX-2 cellular immu-
noreactivity and the clinicopathological pa-
rameters analyzed showed no significant dif-
ferences (P > 0.05; Tables 1 and 2).
Comparison of the immunohistochemi-
cal pattern between the control, UC and
colorectal adenocarcinoma groups was
shown in Figure 1.
No significant correlation was observed
between the three groups regarding the dis-
tribution of COX-1 and COX-2 immunore-
activity in epithelial, mucosal and carcino-
matous cells (P > 0.05 for all comparisons).
The inflammatory cells showed a significant
difference between groups regarding the dis-
tribution of COX-1 and COX-2 immunore-
activity (P = 0.002, P < 0.001, respectively),
with significantly higher positive cases in
the UC group (Figure 2).
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Table 1. Clinical characteristics of ulcerative colitis patients and immunoexpression of cyclooxygenase-1
(COX-1) and -2 (COX-2).
Variables COX-1 positive COX-2 positive
 Epithelium   Infiltrate  Epithelium   Infiltrate
Gender
Male 6 (50.0%) 8 (44.4%) 14 (48.3%) 13 (44.8%)
Female 6 (50.0%) 10 (55.6%) 15 (51.7%) 16 (55.2%)
Age (years)
16-40 6 (50.0%) 9 (50.0%) 11 (62.0%) 13 (44.8%)
41-74 6 (50.0%) 9 (50.0%) 18 (38.0%) 16 (55.2%)
Race
White 5 (41.7%) 9 (50.0%) 17 (58.6%) 15 (51.7%)
Non-white 7 (58.3%) 9 (50.0%) 12 (41.4%) 14 (48.3%)
Disease evolution (years)
0-10 10 (83.3%) 14 (77.8%) 25 (86.2%) 24 (82.8%)
11-22 2 (16.7%) 4 (22.2%) 4 (13.8%) 5 (17.2%)
Disease extension
Proctosigmoiditis 6 (50.0%) 9 (50.0%) 13 (44.8%) 14 (48.3%)
Left-sided colitis 1 (8.3%) 2 (11.1%) 4 (13.8%) 4 (13.8%)
Pancolitis 5 (41.7%) 7 (38.9%) 12 (41.4%) 11 (37.9%)
Clinical activity
Remission 1 (8.3%) 2 (11.1%) 4 (13.8%) 4 (13.8%)
Mild 5 (41.7%) 9 (50.0%) 19 (65.5%) 19 (65.5%)
Moderate 2 (16.7%) 3 (16.7%) 2 (6.9%) 2 (6.9%)
Severe 4 (33.3%) 4 (22.2%) 4 (13.8%) 4 (13.8%)
Data are reported as number with percent in parentheses. P > 0.05 for all tests (chi-square and Fisher exact tests).
Table 2. Histopathological characteristics of ulcerative colitis patients with immunoexpression of cyclooxy-
genase-1 (COX-1)  and -2 (COX-2).
Variables COX-1 positive COX-2 positive
Epithelium    Infiltrate Epithelium     Infiltrate
Erosion/ulceration
Absent 1 (8.3%) 1 (5.6%) 5 (17.2%) 5 (17.2%)
Present 11 (91.7%) 17 (94.4%) 24 (82.8%) 24 (82.8%)
Acute inflammatory process
Absent 0 (0.0%) 0 (0.0%) 2 (6.9%) 2 (6.9%)
Focal crypt epithelial polymorphs 2 (16.7%) 2 (11.2%) 5 (17.2%) 5 (17.2%)
Diffuse crypt epithelial polymorphs 6 (50.0%) 8 (44.4%) 11 (37.9%) 12 (41.4%)
Polymorph exudate 4 (33.3%) 8 (44.4%) 11 (37.9%) 10 (34.5%)
Architectural distortion
Focal crypt architectural irregularity 3 (25.0%) 3 (16.7%) 7 (24.1%) 7 (24.1%)
Diffuse crypt architectural irregularity 6 (50.0%) 8 (44.4%) 12 (41.4%) 12 (41.4%)
Mucosal atrophy 3 (25.0%) 7 (38.9%) 10 (34.5%) 10 (34.5%)
Crypt abscesses
Absent 5 (41.7%) 6 (33.3%) 8 (27.6%) 9 (31.0%)
Present 7 (58.3%) 12 (66.7%) 21 (72.4%) 20 (69.0%)
Lymphoid aggregates
Absent 6 (50.0%) 9 (50.0%) 16 (55.2%) 17 (58.6%)
Present 6 (50.0%) 9 (50.0%) 13 (44.8%) 12 (41.4%)
Paneth cell metaplasia
Absent 10 (83.3%) 15 (83.3%) 22 (75.9%) 23 (79.3%)
Present 2 (16.7%) 3 (16.7%) 7 (24.1%) 6 (20.7%)
Lamina propria lymphoplasmocytosis
Absent 2 (16.7%) 2 (11.1%) 6 (20.7%) 6 (20.7%)
Present 10 (83.3%) 16 (88.9%) 23 (79.3%) 23 (79.3%)
Mucin depletion
Absent 6 (50.0%) 9 (50.0%) 16 (55.2%) 18 (62.1%)
Present 6 (50.0%) 9 (50.0%) 13 (44.8%) 11 (37.9%)
Data are reported as number with percent in parentheses. P > 0.05 for all tests (chi-square and Fisher exact tests).
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Figure 1. Comparison of the im-
munohistochemical pattern be-
tween the control, ulcerative
colitis (UC) and colorectal car-
cinoma groups. Immunohisto-
chemical profile of cyclooxy-
genase-2 (COX-2) in UC: the
arrows indicate the cytoplasmic
staining in epithelial cells (A,B)
and inflammatory cells (C,D).
Profile of cyclooxygenase-1
(COX-1) in UC: the arrows indi-
cate the cytoplasmic staining of
inflammatory cells in crypt ab-
scesses (E) and epithelial cells
(F). Profile of COX-1 in control
group: the arrow indicates the
cytoplasmic staining in epitheli-
al cells (G). Profile of COX-2 in
colorectal cancer: the arrow in-
dicates the cytoplasmic stain-
ing in neoplastic epithelial cells
(H). Magnification = 200X.
Scale bar = 20 µm for all panels.
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Discussion
Inflammation involves plasma-derived
and cellular events normally occurring in
response to tissue injury or infection. In
chronic inflammation, the process continues
due to the persistence of the injury and con-
sequently of the inflammatory mediators.
The focus on salicylates has led to studies on
the arachidonic acid cascade and on COX
and 5-lipoxygenase products. Clinical trials
with non-steroidal anti-inflammatory drugs
in IBD showed no effect or even a detrimen-
tal effect. This finding is in striking contrast
to the efficiency of non-steroidal anti-in-
flammatory drugs in rheumatoid arthritis -
another autoimmune disease involving PGs
- and it might be inferred that COX is of no
relevance in IBD (16-19).
COX-2 was shown to be responsible for
the increase in COX activity in inflamma-
tion; increased concentrations of COX-2 have
been found in synovial tissue during attacks
of rheumatoid arthritis (20). The discovery
of COX-2 reopens the discussion about the
importance of COX products in IBD. It has
been shown that COX-1 and COX-2 exhibit
differences in their sub-cellular localization
and ability to metabolize arachidonic acid
(21).
We found no significant correlation be-
tween positive and negative COX-1 and
COX-2 immunoreactivity in epithelial and
inflammatory cells in cases of UC and clini-
copathological parameters analyzed (P >
0.05). On the other hand, there were cases
with crypt abscesses and lamina propria lym-
phoplasmocytosis with high COX-1 and
COX-2 immunoreactivity.
To the best of our knowledge, no study
has correlated cellular immunoexpression
of COX-1 and COX-2 with the clinicopatho-
logical findings in IBD. However, Hendel
and Nielsen (16), studying the expression of
COX-2 mRNA in IBD, demonstrated a clear
relationship between endoscopic activity and
the relative presence of this expression.
In our series, epithelial cell immunoreac-
tivity of COX-1 was detected in 29% of the
UC patients and immunoreactivity in in-
flammatory cells in 43%. However, low or
no expression of COX-1 was observed in the
control and cancer groups, a finding also
reported by others (4,5,11,22).
The immunoreactivity of COX-2 was
observed in epithelial and inflammatory cells
in 69% of patients with UC, indicating that
this immunoreactivity is strongly induced
not only in lamina propria cells but also in
apical epithelial cells of the colonic mucosa
in IBD (23,24). Analysis of the immunohis-
tochemical results for the various groups
showed a difference in the distribution of
COX-1 and COX-2 in the inflammatory cells,
with a higher proportion of positive cases in
the UC group.
Concerning COX-2, investigators (24-
26) did not detect immunolabeling in normal
epithelium. However, in the present series,
COX-2 immunopositivity in epithelial cells
Figure 2. Comparison of the immunohistochemical results between ulcerative colitis (UC)
and colorectal adenocarcinoma groups and control. The numbers in parentheses are the
number of patients. *P = 0.002 and **P < 0.001 for cyclooxygenase-1 (COX-1) and -2 (COX-
2), respectively, compared to colorectal adenocarcinoma groups (Kruskal-Wallis test).
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was observed in 50% of the control cases, a
fact also reported by Jackson et al. (27).
Other studies have reported that COX-2 is
constitutively expressed in a variety of tis-
sues such as kidney, spine and eyes (28-30).
COX-2 was observed in epithelial cells
of patients with UC, as well as of patients
with colorectal carcinoma. Singer et al. (24),
studying the immunoexpression of COX-1
and COX-2 in UC tissues, Crohn’s disease
and normal epithelium, observed greater
immunolabeling of COX-2 in epithelial cells
of UC and Crohn’s disease samples, sug-
gesting that the persistent expression of this
protein might be related to an increased risk
of carcinogenesis. In fact, large amounts of
COX-2 have been demonstrated in pre-neo-
plastic tissues (31,32) and in various carci-
nomas (33), reflecting the effects of onco-
genes and growth factors which are known
to be inducers of this enzyme (34,35). In
addition, Agoff et al. (36), using molecular
biology and immunohistochemistry, ob-
served that in UC associated with neoplasia
over-expression of COX-2 was present in all
stages of the neoplastic process.
As reported in other studies (5,28), im-
munolabeling of this protein was also fre-
quently observed in fibroblasts.
Based on the present study and on data of
others (37,38), we suggest that COX-1 is not
an exclusively constitutive enzyme and simi-
larly to COX-2, may have a role as a media-
tor of inflammation.
Our data demonstrate that immunohisto-
chemistry permitted the identification of the
COX-1 and COX-2 expression in epithelial
and inflammatory cells of biopsies from UC
patients. COX-2 showed low immunoex-
pression in normal colon and higher expres-
sion in colorectal adenocarcinoma. COX-2
may probably play a role in the pathophysi-
ologic processes of inflammatory bowel dis-
ease and in the development of neoplasia.
Treatment with selective COX-2 inhibitors
might be an additional option for therapy.
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